Menu Search
Equities

Richter Gedeon Vegyeszeti Gyar Nyrt

0QFP:LSE

Richter Gedeon Vegyeszeti Gyar Nyrt

Actions
  • Price (HUF)5,040.00
  • Today's Change0.00 / 0.00%
  • Shares traded352.00
  • 1 Year change0.00%
  • Beta--
Data delayed at least 20 minutes, as of Apr 17 2024 17:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.

  • Revenue in HUF (TTM)805.16bn
  • Net income in HUF158.85bn
  • Incorporated1923
  • Employees12.17k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RICHTER:BUD since
announced		Transaction
value
Richter-Helm Biologics GmbH & Co KGAnnounced06 Mar 202406 Mar 2024Announced-6.25%44.07m
Richter-Helm Biotec GmbH & Co. KGAnnounced06 Mar 202406 Mar 2024Announced-6.25%77.94m
Giskit MD BVAnnounced20 Jul 202320 Jul 2023Announced2.27%33.59m
Data delayed at least 15 minutes, as of Apr 18 2024 15:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.